7 Growth Stocks Holding Up in a Tough Market

Wolfe Research identified seven stocks combining strong earnings, rapid sales growth, and positive momentum in a tough market.

Barrons • Aug 20, 2026

Global Vitiligo Foundation Applauds Incyte's “Moments of Clarity” Campaign for Elevating Patient Voices and Advancing Vitiligo Awareness

MECHANICSBURG, Pa.--(BUSINESS WIRE)--The Global Vitiligo Foundation (GVF) proudly recognizes and supports Incyte's Moments of Clarity campaign, a powerful storytelling initiative that highlights the lived experiences of individuals with nonsegmental vitiligo. Through authentic patient narratives, the campaign closely aligns with GVF's mission to improve the quality of life for people affected by vitiligo through education, advocacy, and community connection. Moments of Clarity captures pivotal.

Business Wire • Aug 17, 2026

Incyte Sales Growth Drives Share Price Gains

Biopharmaceutical company Incyte Corporation (INCY) gets Big Money support to gain 23% so far in 2026.

FXEmpire • Aug 12, 2026

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

Business Wire • Aug 7, 2026

REGN or INCY: Which Is the Better Value Stock Right Now?

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Regeneron (REGN) or Incyte (INCY). But which of these two stocks is more attractive to value investors?

Zacks Investment Research • Aug 5, 2026

Here's Why Incyte (INCY) is a Strong Momentum Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Jul 30, 2026

Incyte Analysts Raise Their Forecasts After Upbeat Q2 Results

Incyte Corp. (NASDAQ:INCY) on Tuesday reported better-than-expected second-quarter results and raised its full-year sales guidance.

Benzinga • Jul 29, 2026

Here's Why Incyte (INCY) is a Strong Growth Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • Jul 29, 2026

Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the EU for Adults with Moderate Atopic Dermatitis.

Business Wire • Jul 29, 2026

Top 3 Health Care Stocks That May Implode This Month

As of July 29, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Benzinga • Jul 29, 2026